Background {#Sec1}
==========

Knowledge of etiology and epidemiology of cancer has great importance for control of cancer, which is a major public health issue across the world due to its high mortality and increasing prevalence \[[@CR1], [@CR2]\]. Over the past few decades, a considerable number of studies have examined factors associated with the occurrence, treatment and outcomes of specific cancer type in many countries \[[@CR3]--[@CR5]\]. Demographic characteristics (including hereditary genetic mutations, age, gender, ethnicity, education, and geographic location), environmental hazards (such as exposure to radiation, smoking, and pollutions), patient health status and behavior (e.g., diet, obesity, physical activity, history of disease, comorbidity and drug use), and health care providers' characteristics (e.g., physicians' knowledge and preferences, prescribing patterns, clinical guidelines and economical considerations) may contribute to variations in cancer incidence, diagnosis, treatment and outcomes between regions \[[@CR6], [@CR7]\]. Better understanding of factors influencing cancer diagnosis and treatments can allow us to improve quality of cancer care and outcomes and facilitate health policy planning.

In the last few years, several studies have assessed the association between geographic variation and incidence of cancer \[[@CR8]--[@CR12]\]. For instance, a US study \[[@CR12]\] found that incidence of colorectal cancer was highest in the Middle Atlantic division, with the lowest rate observed in the Mountain division. Researchers have investigated cancer screening or diagnosis in various geographic locations, and found geographic variations in the uptake of screening and diagnosis of several cancers including cervical, lung and liver cancers \[[@CR13]--[@CR15]\]. Such geographical differences have increased during the past decade in many countries, including Taiwan \[[@CR13]--[@CR17]\]. Cancer treatment and cancer care also vary between geographic locations \[[@CR10], [@CR18]--[@CR21]\]. For example, Reames et al. \[[@CR21]\] reported wide geographic variations in utilization of laparoscopic colectomy among US Medicare patients with colon cancer (from 0% to 66.8% across 306 hospital referral regions). Furthermore, the association between geographic variation and clinical outcomes (such as survival and mortality) of cancer treatment has been investigated extensively \[[@CR8], [@CR9], [@CR22], [@CR23]\]. Andia et al. \[[@CR23]\] indicated that gallbladder cancer mortality rate was higher in the inland and southern regions of Chile, and compared to the north-coastal region, the northern-inland region had a 10-fold higher risk and the southern-inland region had a 26-fold higher risk.

There has been an increasing availability and use of targeted therapies for treatment of cancer due to their high treatment response rates \[[@CR24], [@CR25]\] but less toxic characteristics compared with traditional chemotherapies \[[@CR26]\]. For several cancers, targeted therapies are becoming the main treatments; examples include erlotinib for lung cancer \[[@CR27]--[@CR29]\] and trastuzumab for breast cancer \[[@CR30], [@CR31]\]. With the growing trends in use of targeted therapies, the burden of pharmaceutical expenditure due to their high costs and their accessibility, have lately become one of the most serious concerns in all countries with universal health insurance systems, including Taiwan's national health insurance system. Taiwan's national health insurance system is a compulsory social insurance system in which the coverage rate of its 23 million residents is as high as 99% currently \[[@CR32]\].

Previous research has not addressed whether or not the use of targeted therapies for treatment of cancer differs from region to region in Taiwan \[[@CR33], [@CR34]\]. To provide insights about the accessibility and equity issues related to high-cost targeted therapies, we examined use and costs of antineoplastic agents by geographic region (northern, midwestern, southern, and eastern regions, and the outer islands) in Taiwan, particularly focusing on cancer targeted therapies.

Method {#Sec2}
======

Data sources {#Sec3}
------------

This study used nationwide claims data from the National Health Insurance Research Database (NHIRD), which compiles data of over 99% of population (around 23 million residents) in Taiwan. The database contains information from a mandatory-enrollment and single-payer healthcare system created in 1995, and it covers a wide range of prescription medicines, and inpatient and outpatient medical services \[[@CR35]\]. We obtained 2009-2012 quarterly claims data from NHIRD regarding treatment of malignancies, including details of prescriptions and national health insurance expenditure for antineoplastic agents. The cancer related prescriptions were identified using International Classification of Diseases, 9^th^ edition (ICD-9) diagnosis codes (codes: 140-239). We converted costs in Taiwan dollars to US dollars by 30:1. Our previous studies also used this data source \[[@CR36], [@CR37]\]. In addition, yearly population data by age and region, yearly geographical area by region, yearly number of physician by region were obtained from the Department of Statistics, Taiwan Ministry of Interior \[[@CR38]\]. We obtained population statistics and cancer incidence from Taiwan Cancer Registry Annual Report \[[@CR39]\].

Drugs included {#Sec4}
--------------

We used World Health Organization's Anatomical Therapeutic Chemical (ATC) classification system to identify antineoplastic agents (with code "L01"). We grouped antineoplastic agents into 6 classes based on the ATC system: \[[@CR1]\] targeted therapies (including monoclonal antibodies, protein kinase inhibitors and other targeted therapies). Among targeted therapies: monoclonal antibodies (rituximab, trastuzumab, and cetuximab), protein kinase inhibitors (imatinib, gefitinib, erlotinib, sunitinib, sorafenib, dasatinib, nilotinib, temsirolimus, everolimus, and pazopanib), and bortezomib have been used for the treatment of cancer in Taiwan; \[[@CR2]\] alkylating agents (including nitrogen mustard analogues, alkyl sulfonates, nitrosoureas and other alkylating agents); \[[@CR3]\] antimetabolites (including folic acid analogues, purine analogues and pyrimidine analogues); \[[@CR4]\] plant alkaloids and other natural products (including vinca alkaloids and analogues, podophyllotoxin derivatives and taxanes); \[[@CR5]\] cytotoxic antibiotics and related substances (including actinomycines, anthracyclines and related substances and other cytotoxic antibiotics); and \[[@CR6]\] other agents (including platinum compounds, sensitizers used in photodynamic/radiation therapy and others).

Outcome measures {#Sec5}
----------------

We calculated quarterly and yearly number of prescriptions and costs from 2009 to 2012 to examine the use and costs of each class of antineoplastic agents. We used administrative divisions of Taiwan to group utilization and costs according to the 5 regions: northern, midwestern, southern, and eastern regions and the outer islands ([Appendix 1](#Sec13){ref-type="sec"}). To assess regional differences, we estimated population-adjusted number of targeted therapies prescription and costs (per 100,000 people) for each region. For each region, population-adjusted prescription volume was calculated by using number of prescriptions divided by number of population in that region, and population-adjusted costs was calculated by using total costs divided by number of population in the region. Because cancer incidence by year and across regions was overall stable ([Appendix 2](#Sec14){ref-type="sec"}), we presented population-adjusted results by region.

We also calculated the yearly market shares by prescription volume and by costs for targeted therapies among total antineoplastic agents. Market share by prescription volume was estimated by: number of prescriptions for targeted therapies divided by total number of prescriptions for all antineoplastic agents. The market share by costs was estimated by: costs of targeted therapies divided by total costs of all antineoplastic agents.

Statistical Analysis {#Sec6}
--------------------

We used univariate and multivariate regression models and analysis of variance (ANOVA) to examine the association between 'region' and population-adjusted use and costs of antineoplastic agents. In separate models, we assessed the association between 'region' and population-adjusted use and costs of targeted therapies. We only focused on four regions - northern, midwestern, southern and eastern regions; we excluded the outer islands in these models because its use of antineoplastic agents was much lower than that in other regions. Our models controlled for the following covariates: average age of cancer patients in that region, percentage of male cancer patients in that region, population density (number of population divided by geographic area), physician density (number of physician divided by number of population in the region \* 100,000 people), and cancer incidence per 100,000 population. We also used a time series design with the Autoregressive integrated moving average (ARIMA) model \[[@CR40], [@CR41]\] to estimate longitudinal trends in targeted therapy use and costs. All analyses were carried out with SAS software, Version 9.3 (SAS Institute, Cary, NC).

Results {#Sec7}
=======

Regional variations {#Sec8}
-------------------

Between 2009 and 2012, we observed steady increases in use of all antineoplastic drugs in all regions (ranged from 1.33 to 1.56-fold increase in population-adjusted prescription volume). Use of cancer targeted therapies also more than doubled in all regions except the outer islands (ranged from 2.47 to 2.54-fold increase in population-adjusted prescription volume across regions without considering the outer islands). Table [1](#Tab1){ref-type="table"} presents use and costs by region across years. In 2012, there was a 4.20-fold difference in population-adjusted use of all antineoplastic drugs between the southern region (highest) and the outer islands (lowest) but a 49.11-fold difference in population-adjusted use of targeted therapies between the southern region (highest) and the outer islands (lowest). Without considering the outer islands, there was a 1.25-fold difference in population-adjusted use of antineoplastic drugs between the southern region and the eastern region and a 1.89-fold difference in population-adjusted use of targeted therapies between the southern region and the eastern region in 2012.Table 1Yearly population-adjusted prescription volume and costs of antineoplastic agents by region (2009-2012)RegionYearPopulationPrescription volume and cost of targeted therapies and all antineoplastic agentsNumber of prescriptions of TTNumber of prescriptions of all antineoplastic agentsPopulation adjusted prescription volume of TT per 100,000 peoplePopulation adjusted prescription volume of all antineoplastic agents per 100,000 peopleCost of TT (US\$)Cost of all antineoplastic agents (US\$)Population adjusted Cost of TT per 100,000 peoplePopulation adjusted Cost of all antineoplastic agents per 100,000 peopleNorthern200910,794,02241,5631,200,447385.0611,121.4144,727,732.83245,327,405.57414,3752,272,808201010,852,14653,0851,352,126489.1712,459.5364,066,867.43298,340,256.13590,3612,749,136201110,919,41574,4091,539,869681.4414,102.1280,098,867.07335,228,189.63733,5453,070,020201210,991,480107,4471,681,041977.5515,294.04108,328,729.00369,543,104.87985,5703,362,087Midwestern20095,201,84716,182517,142311.089,941.5117,550,734.80105,008,551.23337,3942,018,67820105,199,84922,116587,463425.3211,297.6925,919,867.20130,844,276.37498,4732,516,30920115,203,79628,424641,058546.2212,319.0531,768,038.03148,131,812.10610,4782,846,61120125,215,94841,136691,949788.6613,266.0345,052,172.70168,569,414.17863,7393,231,808Southern20096,446,72026,808735,122415.8411,403.0427,431,583.03143,013,766.23425,5122,218,39620106,433,34233,836834,331525.9512,968.8637,988,591.17178,074,087.10590,4952,767,98720116,422,58445,262904,722704.7314,086.5748,387,511.27201,906,589.30753,3963,143,69720126,422,53165,905983,2721,026.1515,309.7366,284,538.63223,610,506.801,032,0633,481,657Eastern2009573,4611,25552,193218.859,101.401,872,531.709,729,753.87326,5321,696,6722010569,4781,73660,197304.8410,570.562,248,463.8012,178,410.27394,8292,138,5222011565,1282,41566,179427.3411,710.442,951,519.2714,101,363.17522,2742,495,2512012561,4423,04768,875542.7112,267.523,493,181.9014,396,745.00622,1802,564,244Outer Islands2009103,72212,4310.962,343.7753.30170,837.1751164,7072010107,30803,2610.003,038.920.00316,458.370294,9072011113,98913,6540.883,205.57649.13387,676.10569340,1002012124,421264,53920.903,648.1017,180.40481,334.5313,808386,860*TT* targeted therapies; Population adjusted prescription volume = Number of prescriptions / Population, per 100,000 people; Population adjusted costs = Cost / Population, per 100,000 people

Similarly, population-adjusted costs of all antineoplastic drugs increased from 2009 to 2012 in all regions (ranged from 1.48 to 2.35-fold increase in population-adjusted costs). Costs of cancer targeted therapies also more than doubled in most regions (ranged from 1.91 to 2.56-fold increase in population adjusted costs across regions without considering the outer islands). In 2012, there was a 9.00-fold difference in population-adjusted costs of antineoplastic drugs between the southern region (highest) and the outer islands (lowest) and a 74.74-fold difference in population-adjusted costs of targeted therapies between the southern region (highest) and the outer islands (lowest). Without considering the outer islands, there was a 1.36-fold difference in population-adjusted costs of antineoplastic drugs between the southern region and the eastern region and a 1.66-fold difference in population-adjusted costs of targeted therapies between the southern region and the eastern region in 2012.

Results from univariate and multivariate regression models (without considering the outer lands) are shown in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. For antineoplastic agents, year and region were significantly associated with their costs but they were not associated with the use of these drugs, after adjusting for covariates. Using the southern region as the reference, there was no significant difference in use of antineoplastic agents between regions, but their costs were significantly lower in other regions. Average age of cancer patients, percentage of male cancer patients, and population density were also significantly and positively associated with costs of antineoplastic drugs. For targeted therapies in particular, year and region were not significantly associated with their use although year was associated with their costs. Using the southern region as the reference, there was no significant difference in use and costs of targeted therapies between regions. Percentage of male cancer patients was significantly and positively associated with use and costs of targeted therapies.Table 2Results of ANOVA assessing association between region and use and costs of antineoplastic agents in TaiwanDependent VariableIndependent Variables and ConfoundersUnadjusted F*P*-valueAdjusted F*P*-valuePopulation adjusted prescription volume of antineoplastic agents per 100,000 peopleRegion100.019**\<** ***0.001***3.4560.131Year166.477**\<** ***0.001***1.6720.309Average Age0.4730.529% of Male1.8690.243Population density0.2970.615Physician density0.3520.585Cancer incidence0.0030.959Population adjusted cost of antineoplastic agents per 100,000 peopleRegion61.595**\<** ***0.001***13.735***0.014***Year145.303**\<** ***0.001***132.461**\<** ***0.001***Average Age64.382***0.001***% of Male93.412***0.001***Population density37.111***0.004***Physician density1.3320.313Cancer incidence4.1280.112Population adjusted prescription volume of TT per 100,000 peopleRegion19.165**\<** ***0.001***1.2950.391Year51.340**\<** ***0.001***6.1030.057Average Age0.1520.717% of Male8.368***0.044***Population density0.5460.501Physician density0.7010.449Cancer incidence0.0010.978Population adjusted cost of TT per 100,000 peopleRegion13.449***0.001***2.5570.193Year52.473**\<** ***0.001***16.615***0.010***Average Age0.2630.635% of Male18.796***0.012***Population density0.6150.477Physician density1.4710.292Cancer incidence0.6400.469*TT* targeted therapies; Average Age = average age of cancer patients; % of Male = percentage of male cancer patients; Population density = number of population divided by geographic area; Physician density = number of physician divided by number of population in that region per 100,000 people; bold and italic = significant Table 3Results of multivariate regression model assessing association between region and use and costs of antineoplastic agents in TaiwanDependent VariableIndependent Variables and ConfoundersUnadjusted t*P*-valueAdjusted t*P*-valuePopulation adjusted prescription volume of antineoplastic agents per 100,000 peopleSouthern regionreferencereferenceNorthern region-1.1460.281-0.5650.602Midwestern region-10.056**\<** ***0.001***-0.7330.504Eastern region-14.653**\<** ***0.001***0.4090.703Year 2012referencereferenceYear 2011-5.676**\<** ***0.001***-1.3920.236Year 2010-12.803**\<** ***0.001***-1.2640.275Year 2009-21.100**\<** ***0.001***-1.5540.195Average Age-0.6880.529% of Male1.3670.243Population density0.5450.615Physician density0.5930.585Cancer incidence-0.0550.959Population adjusted cost of antineoplastic agents per 100,000 peopleSouthern regionreferencereferenceNorthern region-0.7030.500-5.797***0.004***Midwestern region-4.448***0.002***- 4.963***0.008***Eastern region-12.106***\<0.001***- 5.519***0.005***Year 2012referencereferenceYear 2011-4.831***0.001***-8.271***0.001***Year 2010-10.996***\<0.001***-7.521***0.002***Year 2009-19.753***\<0.001***-10.691***\<0.001***Average Age8.024***0.001***% of Male9.665***0.001***Population density6.092***0.004***Physician density-1.1540.313Cancer incidence2.0320.112Population adjusted prescription volume of TT per 100,000 peopleSouthern regionreferencereferenceNorthern region-0.8110.438-0.7260.508Midwestern region-3.498***0.007***-0.1070.920Eastern region-6.858***\<0.001***0.5670.601Year 2012referencereferenceYear 2011-5.674***\<0.001***-2.3430.079Year 2010-9.248***\<0.001***-1.3880.238Year 2009-11.659***\<0.001***-1.2470.281Average Age-0.3890.717% of Male2.893***0.044***Population density0.7390.501Physician density0.8380.449Cancer incidence-0.0300.978Population adjusted Cost of TT per 100,000 peopleSouthern regionreferencereferenceNorthern region-0.4670.652-0.7600.490Midwestern region-2.957***0.016***-0.3380.752Eastern region-5.631***\<0.001***0.4890.650Year 2012referencereferenceYear 2011-5.320***\<0.001***-3.813***0.019***Year 2010-8.603***\<0.001***-2.2380.089Year 2009-12.036***\<0.001***-2.3230.081Average Age0.5120.635% of Male4.335***0.012***Population density0.7840.477Physician density1.2130.292Cancer incidence-0.8000.469*TT* targeted therapies; Average Age = average age of cancer patients; % of Male = percentage of male cancer patients; Population density = number of population divided by geographic area; Physician density = number of physician divided by number of population in that region per 100,000 people; bold and italic = significant

Market share of targeted therapies {#Sec9}
----------------------------------

Apart from the outer islands, the market share of targeted therapies by prescription volume for northern, midwestern, southern, and eastern regions of Taiwan was around 5% (4.42%\~6.70%) in 2012, but they accounted for over 25% of costs for all antineoplastic agents (Table [4](#Tab4){ref-type="table"}). The yearly market share of targeted therapies by prescription volume for each region increased almost 2-fold (1.84-1.90) between 2009 and 2012 without considering the outer islands. The southern region had the highest market share by prescription volume (6.70%) in 2012, followed by the northern (6.39%), midwestern (5.94%), and eastern regions (4.42%), and the outer islands (0.57%). This represents about 11.70-fold difference between regions if the outer islands were included; without considering the outer islands, there was only a 1.52-fold difference between regions.Table 4Yearly market share by prescription volume and costs of antineoplastic agents by region (2009-2012)RegionYearMarket share by prescription volume and Costs of targeted therapiesPopulationNumber of prescription for TTNumber of prescription for all antineoplastic agentsMarket share by prescription volume (%)Cost of TT (US\$)Cost of all antineoplastic agents (US\$)Market share by cost (%)Northern200910,794,02241,5631,200,4473.4644,727,733245,327,40618.23201010,852,14653,0851,352,1263.9364,066,867298,340,25621.47201110,919,41574,4091,539,8694.8380,098,867335,228,19023.89201210,991,480107,4471,681,0416.39108,328,729369,543,10529.31Midwestern20095,201,84716,182517,1423.1317,550,735105,008,55116.7120105,199,84922,116587,4633.7625,919,867130,844,27619.8120115,203,79628,424641,0584.4331,768,038148,131,81221.4520125,215,94841,136691,9495.9445,052,173168,569,41426.73Southern20096,446,72026,808735,1223.6527,431,583143,013,76619.1820106,433,34233,836834,3314.0637,988,591178,074,08721.3320116,422,58445,262904,7225.0048,387,511201,906,58923.9720126,422,53165,905983,2726.7066,284,539223,610,50729.64Eastern2009573,4611,25552,1932.401,872,5329,729,75419.252010569,4781,73660,1972.882,248,46412,178,41018.462011565,1282,41566,1793.652,951,51914,101,36320.932012561,4423,04768,8754.423,493,18214,396,74524.26Outer Islands2009103,72212,4310.0453170,8370.032010107,30803,2610.000316,4580.002011113,98913,6540.03649387,6760.172012124,421264,5390.5717,180481,3353.57*TT* targeted therapies; Market share by prescription volume of targeted therapies (%) = number of prescription of targeted therapies for the region/number of prescription of all antineoplastic agents for the same region; Market share by costs of targeted therapies (%) = cost of targeted therapies for the region/cost of all antineoplastic agents for the same region

The yearly market share by costs of targeted therapies for each region also grew around 1.5-fold (1.26-1.61) from 2009 to 2012. The southern region had the highest market share by costs (29.64%) in 2012, followed by the northern (29.31%), midwestern (26.73%), and eastern regions (24.26%), and the outer islands (3.57%). It represents about 8.30-fold difference between regions if the outer islands were included; without considering the outer islands, there was only a 1.22-fold difference between regions.

Trends in use of targeted therapies {#Sec10}
-----------------------------------

We estimated 2009-2012 trends in quarterly market shares by prescription volume and costs for targeted therapies among all antineoplastic agents by region. Figure [1](#Fig1){ref-type="fig"} shows 2009-2012 trends in market share of targeted therapies by prescription volume by region. In the southern region (region with the highest rate in 2012), the quarterly market share of targeted therapies by prescription volume rose rapidly from 3.39% in the first quarter of 2009 to 7.05% in the fourth quarter of 2012. Figure [2](#Fig2){ref-type="fig"} shows 2009-2012 trends in market share by costs by region. In the southern region (region with the highest rate in 2012), the quarterly market share by costs of targeted therapies rose rapidly from 18.51% in the first quarter of 2009 to 32.19% in the fourth quarter of 2012.Fig. 12009-2012 trend in market share of targeted therapies by prescription volume among total antineoplastic agents by region in Taiwan Fig. 22009-2012 trend in proportion of costs for targeted therapies among total antineoplastic agents by region in Taiwan

Discussion {#Sec11}
==========

Our present study is the first study that estimated the longitudinal trend in use and costs of antineoplastic agents including targeted therapies for cancer treatment by geographic region in Taiwan. Overall our findings do not indicate a significant association between region and use of antineoplastic drugs or use of targeted therapies, after controlling for confounders. Our results suggest an association between region and costs of antineoplastic drugs but we did not find an association between region and costs of targeted therapies. We observed small differences in population-adjusted use of all antineoplastic drugs and a 2-fold difference in use of targeted therapies between regions except the outer islands; the outer islands had substantially lower use of antineoplastic drugs.

Previous studies suggested cancer incidence and physician density as determinants of prescription \[[@CR42], [@CR43]\]. However, we did not identify these as significant predictors of use and costs of antineoplastic agents or of targeted therapies, after adjusting for covariates including region. It might be because cancer incidence was similar across regions. Access to oncologists might be more important than physician density in the case of access to cancer treatments but there is a lack of information to estimate oncologist density. Our study suggests that average age of cancer patients and percentage of male cancer patients were associated with costs of antineoplastic drugs but they were not associated with use of antineoplastic drugs. These variables might be related to dosing which would impact the overall treatment costs but not the prescription. Furthermore, percentage of male cancer patients was associated with both use and costs of targeted therapies. This is not surprising because lung cancer and colorectal cancer, two of the top three cancers accounting for targeted therapy use have higher prevalence in men \[[@CR33], [@CR39]\].

The difference in use of antineoplastic drugs and targeted therapies between the outer islands and other regions were greater than the difference in cancer incidence between these regions. In addition, there was almost no use of targeted therapies until 2012 in the outer islands, suggesting late adoption of new treatments in this region. It may reflect the limited availability of specialist care and hospitals in the outer islands, and patients with cancer in this region may seek and receive cancer treatments in hospitals in other regions instead \[[@CR44]\]. To reduce the gap in access to targeted therapies and other antineoplastic drugs between the outer islands and other regions, more efforts might be needed to improve accessibility to care, including diagnosis and treatment of cancer, in the outer islands, or government support for people to travel to the southern region (the region closest to the outer islands) to receive care.

Our findings show that while the market share of targeted therapies by prescription volume increased from 3% in 2009 to 6% in 2012 without considering the outer islands, their market share by costs increased from about 20% in 2009 to about 30% in 2012. Growing trends in use and costs of targeted therapies for cancer treatment is likely to continue in Taiwan and in all of its regions, which may cause increasing economic burden. In Taiwan, similar to many other countries, health technology assessment to restrict coverage, prior authorization, and higher out-of-pocket costs by patients have been used to relief some economic burden for the national health system. The high cost of targeted therapies may continue to be a barrier to access for patients with cancer \[[@CR45], [@CR46]\]. Increasing economic burden on cancer care overall due to growing use of high-cost targeted therapies challenges the sustainability of the universal insurance system because there might be 'trade-offs' to be made with reimbursements for non-cancer services and treatments. It is important that policymakers revisit the pricing and reimbursement structures for targeted therapies due to their high prices especially because some therapies have little rigorous effectiveness and safety evidence \[[@CR47]--[@CR50]\]. Strategies are needed to ensure patient access to effective health services and treatments without overspending the healthcare budget.

The high costs of cancer targeted therapies and their increasing use for many cancers are issues of growing attention globally because cancer incidence is expected to rise worldwide, from 14 million newly diagnosed patients annually in 2012 to 22 million within the next two decades \[[@CR51]\]. With the high costs of cancer care, research should investigate regional inequities in treatment that can results in inequities in health outcomes. Such research is important to inform policy and program implementation to reduce inequities.

There are some limitations to this study. First, this study aimed to examine the recent trends in utilization of antineoplastic drugs particularly cancer targeted therapies by geographic region in Taiwan. We did not analyze the prescribing patterns of antineoplastic drugs and targeted therapies by patient/physician characteristics, and by other environmental factors (number of hospitals, cancer clinics etc). Second, this study examined the trend in overall targeted therapy use, we did not categorize targeted therapies by their pharmacological classification (e.g., protein kinase inhibitors) and indications (types of cancers). Third, our model included physician density by region as a confounder. It would be more precise to estimate and adjust for oncologist density by region; however, this information was not available. Nonetheless, this study should provide a basis for additional research. Further research is needed on geographic variations in cancer screening and diagnosis in Taiwan, and in use of antineoplastic drugs particularly targeted therapies considering other factors such as patient characteristics, physician preferences, and classes of targeted therapies. Studies are also warranted to better understand access to cancer care and treatment in the outer islands.

Conclusion {#Sec12}
==========

This study estimated the nationwide, longitudinal trend in use and costs of antineoplastic drugs by geographic region in Taiwan with a focus on targeted therapies. Overall, we found some geographic variations in use of antineoplastic drugs in Taiwan; use was notably low in the outer islands. Similar to other countries, growing trend in use and costs of targeted therapies for cancer treatment is likely to continue in Taiwan, which may cause increasing economic burden. Strategies might be needed to ensure access to cancer care in each region as economic burden of cancer care increase due to growing use of high-cost targeted therapies.

Appendix 1 {#Sec13}
==========

Table 5Classification of regions in this studyRegionAdministrative divisionsNorthern[Taipei City](http://en.wikipedia.org/wiki/Taipei), [New Taipei City](http://en.wikipedia.org/wiki/New_Taipei), [Keelung City](http://en.wikipedia.org/wiki/Keelung), [Hsinchu City](http://en.wikipedia.org/wiki/Hsinchu), [Hsinchu County](http://en.wikipedia.org/wiki/Hsinchu_County), [Taoyuan City](http://en.wikipedia.org/wiki/Taoyuan_City), [Yilan County](http://en.wikipedia.org/wiki/Yilan_County,_Taiwan), [Miaoli County](http://en.wikipedia.org/wiki/Miaoli_County)Midwestern[Taichung City](http://en.wikipedia.org/wiki/Taichung), [Changhua County](http://en.wikipedia.org/wiki/Changhua_County), [Nantou County](http://en.wikipedia.org/wiki/Nantou_County)Southern[Tainan City](http://en.wikipedia.org/wiki/Tainan), [Yunlin County](http://en.wikipedia.org/wiki/Yunlin_County), [Chiayi City](http://en.wikipedia.org/wiki/Chiayi), [Chiayi County](http://en.wikipedia.org/wiki/Chiayi_County), [Kaohsiung City](http://en.wikipedia.org/wiki/Kaohsiung), [Pingtung County](http://en.wikipedia.org/wiki/Pingtung_County)Eastern[Taitung County](http://en.wikipedia.org/wiki/Taitung_County), [Hualien County](http://en.wikipedia.org/wiki/Hualien_County)Outer islands[Kinmen County](http://en.wikipedia.org/wiki/Kinmen), [Penghu County](http://en.wikipedia.org/wiki/Penghu), [Lienchiang County](http://en.wikipedia.org/wiki/Matsu_Islands)

Appendix 2 {#Sec14}
==========

Table 6Cancer Incidence, Population Density and Physician Density by year and regionRegionYearCancer Incidence (per 100,000 people)Population Density (people per hectare)Physician Density (doctor per 100,000 people)Northern200936612.38167.94201038112.26171.49201138412.32176.16201239912.40179.87Midwestern20093726.34163.5420103776.31167.8620113926.32172.7520124036.34175.21Southern20094026.64159.0320104216.58163.8320114316.56167.6520124526.55170.88Eastern20093870.72173.3320104130.72174.9020114250.71179.9620124470.71185.42Outer Islands20091896.9792.5320101977.1197.9320112247.3490.4620122387.7495.40

\% of Male

:   Percentage of male cancer patients

ANOVA

:   Analysis of variance

ARIMA

:   Autoregressive integrated moving average

ATC

:   Anatomical Therapeutic Chemical

Average Age

:   Average age of cancer patients

ICD-9

:   International Classification of Diseases, 9th edition

NHIRD

:   National Health Insurance Research Database

TT

:   Targeted therapies
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